Aptus Pharma Limited

Aptus Pharma reported standalone FY26 revenue of ₹46.71 crore, up 89.59% YoY, with EBITDA at ₹7.50 crore. The company expanded its product portfolio to 250+ formulations across chronic, acute, and wel

Board approved audited FY26 results showing 49% net profit growth to ₹4.62 crore and declared 3:2 bonus shares. Company fixed 12 May 2026 as record date for bonus issue following shareholder approval

Aptus Pharma Limited filed a regulatory statement confirming no deviations in utilization of ₹13.02 crore IPO proceeds raised on September 29, 2025. All funds were fully utilized as per original objec

Aptus Pharma shareholders approved two resolutions via postal ballot: increasing authorized share capital and issuing bonus shares in a 3:2 ratio. All resolutions passed unanimously with 100% votes in

Promoter Tejash Maheshchandra Hathi discloses acquisition of 10,000 equity shares in Aptus Pharma Limited via off-market transaction on May 11, 2026. The acquisition increases his total holding to 785

Promoter Ghanshyam Pansuriya disclosed acquisition of 14,000 equity shares in Aptus Pharma Limited via off-market inter-se transfer. His total holding increased from 5.10% to 5.31% of the company's vo

Kapilbhai Hasmukhbhai Chandarana, a promoter group member, acquired 10,000 equity shares of Aptus Pharma Limited on May 11, 2026. The acquisition increased his total holding from 775,000 shares (11.30

Aptus Pharma discloses non-applicability of SEBI LODR Regulation 24A due to its SME Exchange listing. The company cites Regulation 15(2) as the basis for exemption from submitting the Annual Secretari